Overview

OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

Status:
Completed

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

Summary

The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitis

Phase:

Phase 3

Details

Lead Sponsor:

Ocular Therapeutix, Inc.

Collaborator:

ORA, Inc.

Treatments:

Dexamethasone